Split hand-foot malformation 2

Summary

Split hand-foot malformation 2 (MONDO:0010736) is a disease. A subtype of split hand-foot malformation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	split hand-foot malformation 2
Mondo ID	MONDO:0010736
MeSH	C564056
OMIM	313350
DOID	DOID:0090027
UMLS	C1839258
MedGen	326848
GARD	0015308
Is cancer (heuristic)	no

Also known as: SHFD2 · SHFM2 · SHSF2 · split hand foot anomaly - X-linked · split hand foot deformity 2 · split hand-foot malformation type 2 · split hand/foot malformation 2 · split hand/foot malformation X-linked · split-hand/foot malformation 2

Disease family

This is a subtype of split hand-foot malformation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › split hand-foot malformation › split hand-foot malformation 2

Related subtypes (5): split hand-foot malformation 1, split hand-foot malformation 6, split hand-foot malformation 3, split hand-foot malformation 4, split hand-foot malformation 5

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.